Leg Injuries and Disorders
Also known as: Thighs, Femurs, Femoral, Trauma, Pain
Methodology & AI Transparency ⓘ
Leg Injuries and Disorders Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Your legs are made up of bones, blood vessels, muscles, and other connective tissue.
- 2 Real-world patient consensus: Clinical coding for Leg Injuries and Disorders uses ICD-10 S89.90XA across Arthritis & Joints specialty care.
- 3 Typical cash cost range: Workup highlights for Leg Injuries and Disorders (S89.90XA): urate-lowering titration [Leg Injuries and Disorders S89.90XA].
- 4 Top reported side effects / signs: Longitudinal Leg Injuries and Disorders monitoring tracks Serum Uric Acid in Leg Injuries and Disorders (S89.90XA: (Gout Target)) toward < 6.0 mg/dL (< 5.0 mg/dL with tophi) (S89.90XA).
Ask our AI Specialists anything about Leg Injuries and Disorders
What Is Leg Injuries and Disorders?
Your legs are made up of bones, blood vessels, muscles, and other connective tissue. They are important for motion and standing. Playing sports, running, falling, or having an accident can damage your legs. Common leg injuries include sprains and strains , joint dislocations , and fractures (broken bones). These injuries can affect the entire leg, or just the foot , ankle , knee , or hip . Certain diseases also lead to leg problems. For example, knee osteoarthritis, common in older people, can cause pain and limited motion. Problems in your veins in your legs can lead to varicose veins or deep vein thrombosis .
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Leg Injuries and Disorders (S89.90XA) center on monosodium urate or in Leg Injuries and Disorders (S89.90XA: calcium pyrophosphate crystal). Cross-referenced with NIH MeSH (Leg Injuries, Femoral Fractures), targeted arthritis & joints interventions aim to normalize Serum Uric Acid in Leg Injuries and Disorders (S89.90XA: (Gout Target)).
Common Symptoms & Clinical Signs
- • Presentation of Leg Injuries and Disorders (S89.90XA): localized tendon or in Leg Injuries and Disorders (S89.90XA: bursa tenderness limiting)
- • Secondary Leg Injuries and Disorders clinical sign: activity-related deep aching in Leg Injuries and Disorders (S89.90XA: joint pain in)
- • Symptom flares in Leg Injuries and Disorders correlating with Serum Uric Acid in Leg Injuries and Disorders (S89.90XA: (Gout Target)) deviation outside < 6.0 mg/dL (< 5.0 mg/dL with tophi) (S89.90XA)
- • Functional arthritis & joints impact requiring urate-lowering titration [Leg Injuries and Disorders S89.90XA] evaluation (S89.90XA)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Leg Injuries and Disorders Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | S89.90XA | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Uric Acid in Leg Injuries and Disorders (S89.90XA: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (S89.90XA) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Leg Injuries and Disorders (S89.90XA: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (S89.90XA) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Leg Injuries and Disorders S89.90XA] | Preserved joint-space width (S89.90XA) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Leg Injuries and Disorders
Treatment selection for Leg Injuries and Disorders depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Leg Injuries and Disorders)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA: What a 642-Participant Study Found In this trial of patients with active PsA who had inadequate response or intolerance to at least one biologic DMARD, upadacitinib 15 mg and 30 mg was more effective than placebo over 24 weeks in improving signs and symptoms of... Annals of the rheumatic diseases • 2021-03-15 • Phase III Randomized Trial | N = 642 | 93/100 | PMID 33272960 ↗ |
| Can This Approach Help? Inside the Latest Research on Inhibition of structural damage progression with the selective interleukin-23 Guselkumab, a fully human monoclonal antibody able to bind CD64 and simultaneously inhibit the IL-23p19 subunit, provided significantly higher rates of clinical improvement and significant inhibition of structural damage... Annals of the rheumatic diseases • 2025-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40962616 ↗ |
| Can This Approach Help? Inside the Latest Research on Resolution of enthesitis by guselkumab and relationships to disease burden: Guselkumab resulted in higher proportions of PsA patients with resolved enthesitis by week 24, with maintenance of resolution rates through 1 year. Rheumatology (Oxford, England) • 2021-11-03 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33822898 ↗ |
| Can This Approach Help? Inside the Latest Research on Anti-drug antibodies and neutralising antibodies on safety and real-world ADA induction had no apparent impact on safety. Modern rheumatology • 2026-08-31 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 41717779 ↗ |
Leg Injuries and Disorders Patient Community & “People Like Me” Threads
Filter Leg Injuries and Disorders community threads and patient logs by age, biological sex, dosage, and treatment duration.